Close Menu

NEW YORK – A triple-pronged therapy that simultaneously targets BRAF, EGFR, and MEK seems to stretch out overall survival times in BRAF-mutated metastatic colorectal cancer cases, according to results from a randomized Phase III clinical trial called BEACON.

"We're hopeful that this will give new options for our [BRAF-mutated metastatic CRC] patients," said Scott Kopetz, a gastrointestinal medical oncologist at the University of Texas MD Anderson Cancer Center, principal investigator on BEACON and co-lead for MD Anderson's Cancer Moon Shot effort in CRC.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.